Fundamentals for Merck & Co., Inc.
MRK's low growth in both earnings and revenue signals a potential profit decline. This could be a sign of financial trouble, suggesting that the company's profitability mig...
Business Operations:
Sector: HealthcareIndustry: Drug Manufacturers - General
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Revenue projections:
Financial Ratios:
| currentRatio | 1.352000 |
|---|---|
| forwardPE | 16.484856 |
| debtToEquity | 119.928000 |
| earningsGrowth | -0.120000 |
| revenueGrowth | 0.047000 |
| grossMargins | 0.751980 |
| operatingMargins | 0.352230 |
| trailingEps | 0.990000 |
| forwardEps | 8.980970 |
MRK's current ratio of 1.352 means the company has enough liquidity to meet its short-term debt obligations. With sufficient cash reserves and current assets, MRK can comfortably cover its liabilities, reflecting a strong financial outlook.
MRK's Forward PE is in a strong range, indicating that its stock price compares well with its earnings. The stock is not considered overpriced, leaving ample room for growth and making it a promising option for investors looking for value and future returns.
MRK's high debt-to-equity ratio signals that the company is heavily leveraged. This suggests MRK may be relying more on debt than equity to finance its operations, which could expose the company to greater financial risk in challenging economic conditions.
MRK's low growth in both earnings and revenue signals a potential profit decline. This could be a sign of financial trouble, suggesting that the company's profitability might shrink in the near future.
With positive gross and operating margins, MRK demonstrates strong profitability. This reflects the company's ability to manage costs and maintain healthy profits, showcasing effective operational efficiency and financial stability.
Price projections:
Insider Transactions:
There were 12 MRK stock sales, with market price at 117.37166659037273.During the review period, no sell transactions were executed.The trend of more buys than sells at MRK's current price levels suggests a possible bullish sentiment. This could indicate that investors are expecting a favorable outlook for the stock, prompting more buying activity.
Recommendation changes over time:
With analysts showing a buy bias for MRK, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning MRK as a safe and profitable place for investors to allocate their funds and seek growth.